All Stories

  1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2026
  2. Bioassay protocol metadata annotation: Proposed standards adoption
  3. BindingDB in 2024: a FAIR Knowledgebase of Protein-Small Molecule Binding Data
  4. Hydrolases in GtoPdb v.2023.1
  5. Bio-Aurac – an open-source browser plugin to better navigate literature content
  6. The IUPHAR/BPS guide to PHARMACOLOGY in 2022: curating pharmacology for COVID-19, malaria and antibacterials
  7. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
  8. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
  9. Will the Chemical Probes Please Stand Up?
  10. Will the chemical probes please stand up?
  11. A rational roadmap for SARS‐CoV‐2/COVID‐19 pharmacotherapeutic research and development. IUPHAR Review 29
  12. Déjà vu: Stimulating open drug discovery for SARS-CoV-2
  13. Opening up connectivity between documents, structures and bioactivity
  14. Déjà vu: Stimulating Open Drug Discovery for SARS-CoV-2
  15. The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology
  16. Opening up Connectivity Between Documents, Structures and Bioactivity
  17. Hydrolases (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
  18. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
  19. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
  20. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  21. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
  22. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
  23. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors
  24. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
  25. The IUPHAR/BPS Guide to PHARMACOLOGY in 2020: extending immunopharmacology content and introducing the IUPHAR/MMV Guide to MALARIA PHARMACOLOGY
  26. Hydrolases (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
  27. Inverse pharmacology: Approaches and tools for introducing druggability into engineered proteins
  28. Towards Academic Drug Development Guidelines
  29. A new guide to immunopharmacology
  30. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY
  31. SynPharm - a new tool to help Synthetic Biologists create proteins which respond to existing drugs
  32. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY
  33. An open-access tool for designing drug control into engineered proteins
  34. Accessing Expert-Curated Pharmacological Data in the IUPHAR/BPS Guide to PHARMACOLOGY
  35. Caveat Usor: Assessing Differences between Major Chemistry Databases
  36. An open-access tool for designing drug control into engineered proteins
  37. Challenges of Connecting Chemistry to Pharmacology: Perspectives from Curating the IUPHAR/BPS Guide to PHARMACOLOGY
  38. Can we devise new therapies by combining databases of protein interactions and of drug targets?
  39. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors
  40. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Other ion channels
  41. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
  42. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters
  43. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors
  44. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand-gated ion channels
  45. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors
  46. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview
  47. THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Voltage-gated ion channels
  48. Counting human proteins
  49. OUP accepted manuscript
  50. Selected GPCR resources
  51. Illustrating and homology modeling the proteins of the Zika virus
  52. The endothelin hormones, structure and function
  53. Modeling the proteins in the Zika virus
  54. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors
  55. A focus on the enzymes for which there is pharmacological or therapeutic interest
  56. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors
  57. The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels
  58. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors
  59. The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels
  60. The Concise Guide to PHARMACOLOGY 2015/16: Transporters
  61. The Concise Guide to PHARMACOLOGY 2015/16: Voltage-gated ion channels
  62. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands
  63. Addressing the next viral outbreak
  64. Expanding opportunities for mining bioactive chemistry from patents
  65. How do we fight the next pathogen we discover?
  66. Associated challenges with the divergent expansions of public and commercial sources of molecules
  67. Comparing the Chemical Structure and Protein Content of ChEMBL, DrugBank, Human Metabolome Database and the Therapeutic Target Database
  68. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
  69. Tracking 20 Years of Compound-to-Target Output from Literature and Patents
  70. Extracting and connecting chemical structures from text sources using chemicalize.org
  71. BACE2 as a new diabetes target: a patent review (2010 – 2012)
  72. InChI in the wild: an assessment of InChIKey searching in Google
  73. Challenges associated with obtaining chemical structures of repurposing candidates from an online DB
  74. A tale of two drug targets: the evolutionary history of BACE1 and BACE2
  75. Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group
  76. SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data
  77. Mapping Between Databases of Compounds and Protein Targets
  78. Making every SAR point count: the development of Chemistry Connect for the large-scale integration of structure and bioactivity data
  79. Minimum information about a bioactive entity (MIABE)
  80. Analysis of in vitrobioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds
  81. Towards BioDBcore: a community-defined information specification for biological databases
  82. Towards BioDBcore: a community-defined information specification for biological databases
  83. The Cinderella of Biological Data Integration: Addressing Some of the Challenges of Entity and Relationship Mining from Patent Sources
  84. Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds
  85. The Yoyo Has Stopped: Reviewing the Evidence for a Low Basal Human Protein Number
  86. Thrombin-induced fibrinopeptide release from a fibrinogen variant (fibrinogen Sydney I) with an Aα Arg-16 → His substitution
  87. Proteases: Evolution
  88. Complementarity Between Public and Commercial Databases: New Opportunities in Medicinal Chemistry Informatics
  89. Exploiting new genome data and Internet resources for the phylogenetic analysis of proteases, substrates and inhibitors
  90. Finding, Delineating and Analysing Genes
  91. Proteases: Evolution
  92. Has the yo-yo stopped? An assessment of human protein-coding gene number
  93. Splice variants: A homology modeling approach
  94. The HtrA Family of Proteases
  95. The characterisation of novel secreted Ly-6 proteins from rat urine by the combined use of two-dimensional gel electrophoresis, microbore high performance liquid chromatography and expressed sequence tag data
  96. Identification, Genomic Organization, and mRNA Expression of LACTB, Encoding a Serine β-Lactamase-like Protein with an Amino-terminal Transmembrane Domain
  97. A genomic perspective on human proteases as drug targets
  98. A genomic perspective on human proteases
  99. Website Review: InterPro (The Integrated Resource of Protein Domains and Functional Sites). http://www.ebi.ac.uk/interpro/
  100. ASP1 (BACE2) Cleaves the Amyloid Precursor Protein at the β-Secretase Site
  101. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response
  102. THE VERTEBRATE HTRA SERINE PROTEASE FAMILY; A NEW EXAMPLE OF HORIZONTAL GENE TRANSFER
  103. Sequencing, tissue distribution and chromosomal assignment of a novel ubiquitin-specific protease USP23
  104. Assessing the protease and protease inhibitor content of the human genome
  105. The Impact of Genomics on Drug Discovery
  106. InterPro (The Integrated Resource of Protein Domains and Functional Sites)
  107. Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase
  108. Disposable Microbore High-Pressure Liquid Chromatography Columns for Protein and Peptide Separations
  109. Synergistic scale-down of three protein micropreparation techniques
  110. CHROMATOGRAPHIC CARBON AS AN INERT SAMPLE ADSORBENT FOR PROTEIN SEQUENCING
  111. Analytical and micropreparative capillary electrophoresis of the peptides from calcitonin
  112. Separation by capillary electrophoresis followed by dynamic elution
  113. Bovine dopamine .beta.-hydroxylase, primary structure determined by cDNA cloning and amino acid sequencing
  114. Inactivation of dopamine β-hydroxylase by p-cresol: Evidence for a second, minor site of covalent modification at tyrosine 357
  115. Purification to apparent homogeneity and partial amino acid sequence of rat liver O 6 -alkylguanine-DNA-alkyltransferase
  116. Sequence similarity between dopamine β‐hydroxylase and peptide α‐amidating enzyme: Evidence for a conserved catalytic domain
  117. Inactivation of dopamine .beta.-hydroxylase by .beta.-ethynyltyramine: kinetic characterization and covalent modification of an active site peptide
  118. THE USE OF GLASS CAPILLARY TUBES AS DISPOSABLE MICROBORE COLUMNS FOR RP-HPLC OF PROTEINS AND PEPTIDES
  119. Inactivation of dopamine .beta.-hydroxylase by p-cresol: isolation and characterization of covalently modified active site peptides
  120. The nitroreductase enzyme in walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-YL)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
  121. Use of sep-pak cartridges for on-line preparative high-performance liquid chromatography
  122. Amino acid sequence of β‐galactoside‐binding bovine heart lectin
  123. Direct analysis of plasma fibrinogen‐derived fibrinopeptides by high‐performance liquid chromatography: investigation of nine congenital fibrinogen abnormalities
  124. Direct analysis of plasma fibrinogen-derived fibrinopeptides by high-performance liquid chromatography
  125. COVALENT STRUCTURE OF FIBRINOGEN
  126. Fibrinogen Manchester: identification of an abnormal fibrinopeptide A with a C-terminal arginine→histidine substitution
  127. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the Aα 16 Arg → His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide
  128. The ELIXIR Database Provider Survey
  129. Finding, Delineating and Analysing Genes
  130. Internet Resources for the Geneticist
  131. A Bioinformatics Perspective on Genetics in Drug Discovery and Development